Northern Bio

Northern Bio is a privately held, revenue-generating preclinical CRO founded in 2018, providing specialized research services to biotech and pharmaceutical sponsors. Its core expertise lies in complex neurosurgical and ophthalmological models, advanced bioanalysis (including molecular biology and ligand binding assays), and a strong commitment to animal welfare via the 3Rs principle. The company is positioned to capitalize on the growing demand for outsourced preclinical research, particularly in advanced therapies like gene and cell treatments, leveraging its scientific niche and collaborative partnership model.

Integrated preclinical CRO platform specializing in advanced surgical models for targeted CNS/ophthalmic drug delivery and a bioanalytical suite for molecular biology (qPCR, dPCR, ligand binding) supporting gene/cell therapy development.

Competes with large, full-service global CROs (e.g., Charles River, Labcorp) that have specialized neuroscience units and with other boutique preclinical CROs focusing on complex models. Differentiation is based on deep surgical expertise, flexibility for non-standard studies, and a strong focus on the advanced therapy sector.